Click here to view the United Healthcare (UHC) Medical Policy Updates » November 2024 United…
BCBS Federal Employee Program (FEP) Medical Policy Updates – January 2023
January 2023 BCBS Federal Employee Program (FEP) Medical Policy Updates:
- Abecma idecabtagene vicleucel
- Absorbable Nasal Implant for Treatment of Nasal Valve Collapse
- Acthar gel corticotropin
- Adcirca Alyq Tadliq tadalafil
- Adempas riociguat
- Adoptive Immunotherapy
- Afinitor everolimus
- Afrezza insulin human
- Aliqopa copanlisib
- Allogeneic Pancreas Transplant
- Alpha1 Proteinase Inhibitors
- Amitiza lubiprostone
- Amphetamines
- Ampyra dalfampridine
- ART Drugs
- Arzerra ofatumumab
- Aubagio teriflunomide
- Balloon Dilation of the Eustachian Tube
- BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
- Bevacizumab
- Bone Density Studies
- Bosulif bosutinib
- Botox onabotulinum toxin A
- Brexafemme ibrexafungerp
- Breyanzi lisocabtagene maraleucel
- Brukinsa zanubrutinib
- Buphenyl Pheburane sodium phenylbutyrate
- Bynfezia octreotide acetate
- Calquence acalabrutinib
- Carbaglu carglumic acid
- Cardiac Applications of Positron Emission Tomography Scanning
- Carvykti ciltacabtagene autoleucel
- CGM Supplies
- Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss
- Cialis tadalafil
- Cimzia certolizumab pegol
- Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
- Composite Tissue Allotransplantation of the Hand and Face
- Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
- Computed Tomography Perfusion Imaging of the Brain
- Computed Tomography to Detect Coronary Artery Calcification
- Condoms
- Contrast-Enhanced Computed Tomographic Angiography for Coronary Artery Evaluation
- Copiktra duvelisib
- Cosentyx secukinumab
- Cranial Electrotherapy Stimulation and Auricular Electrostimulation
- Cresemba isavuconazonium
- Cryosurgical Ablation of Primary Metastatic Liver Tumors
- Diacomit stiripentol
- Dihydroergotamine Nasal Sprays
- Dupixent dupilumab
- Enbrel etanercept
- Entadfi finasteride and tadalafil
- Entyvio IV vedolizumab
- Epidiolex cannabidiol
- Erleada apalutamide
- Esbriet pirfenidone
- Evaluation of Biomarkers for Alzheimer Disease
- Evenity romosozumabaqqg
- Exjade Jadenu deferasirox
- Ferriprox deferiprone
- Firdapse amifampridine
- Flolan Veletri epoprostenol
- Focal Treatments for Prostate Cancer
- Fyarro sirolimus proteinbound
- Gabapentin
- Gazyva obinutuzumab
- Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer
- Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
- Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- Genetic Testing for Mitochondrial Disorders
- Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, Tumor Mutational Burden, Microsatellite Instability/Mismatch Repair)
- Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden)
- Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
- Gilenya Tascenso ODT fingolimod
- Gleevec imatinib
- GnRH GD
- Heart Transplant
- Heart/Lung Transplant
- Humira adalimumab
- Hyftor sirolimus
- Ibsrela tenapanor
- Iclusig ponatinib
- Ilumya tildrakizumabasmn
- Imbruvica ibrutinib
- Imcivree setmelanotide
- Infliximab
- Injectable Bulking Agents for Treatment of Urinary and Fecal Incontinence
- Insulin GLP-1 Combinations
- Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment
- Islet Transplantation
- Isolated Small Bowel Transplant
- Isturisa osilodrostat
- Itraconazole
- IVIG intravenous immunoglobulin
- JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms
- Kadcyla adotrastuzumab emtansine
- Kalydeco ivacaftor
- Kesimpta ofatumumab
- Ketoconazole
- Kidney Transplant
- Kymriah tisagenlecleucel
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
BCBS Federal Employee Program (FEP)